155 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
research and development
Regulation S-K promulgated under the Securities Act
REMS
Risk Evaluation and Mitigation Strategy
RewinD-LB Trial
our Phase … condition and its ability to pursue its business strategy. If the Company is unable to secure additional capital in sufficient amounts or on terms
8-K
EX-10.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
, methodology, algorithm, machine, development, product, service, technology, strategy, software, work of authorship or other Works (as defined in Section 4.13
8-K
EX-99.1
rip7dg 1rymj6
5 Mar 24
Regulation FD Disclosure
8:51am
8-K
EX-99.2
ekr35ml196mos0fw079
7 Feb 24
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
4:06pm
8-K
EX-10.3
o7tunhdzrshclid0o
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.2
fkagn
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
pk3mn4
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
s2ytkbg7nwxsoy
5 Jan 24
CervoMed to Participate in the Emerging Growth Conference 66
4:05pm
8-K
EX-10.1
3kubo8pgg5rw1 owckwh
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm
8-K/A
EX-99.3
rygf3dk5
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.2
upq3arxm2ibjtsvw
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
425
EX-99.2
qkxileflufd
9 Aug 23
Business combination disclosure
4:02pm
8-K
EX-99.2
129ymiws4jolk12
9 Aug 23
Other Events
4:02pm
424B3
dvc9rq8 307
13 Jul 23
Prospectus supplement
4:32pm